Jarrod Longcor, Chief Operating Officer at Cellectar Biosciences, Inc. (CLRB), bought 8,680 shares at $2.88 ($25K) on 2026-05-07, disclosed to the SEC on 2026-05-11.
COO Jarrod Longcor purchased 8,680 shares at $2.88 on May 7, 2026, marking the largest insider purchase in the company's history. This significant buy from a C-suite executive suggests confidence in the company's recent clinical and regulatory progress.
The stock is trading at $3.08, up 16.89% over the past five days and 9.61% over the last month, though it remains down 7.78% over the last 90 days and is currently 25.71% above its 52-week low of $2.45.
Q1 2026 earnings call on May 14, 2026; Phase 2b data showing durable responses in Waldenström Macroglobulinemia on May 5, 2026; and a Zacks upgrade to Buy on May 7, 2026.
Recent earnings highlights note 'ongoing financial hurdles' and the company is 'navigating financial hurdles for future growth,' indicating potential cash flow challenges despite clinical progress.
Something here stands out, but not much.
| Filing → |
| CLRB | BUY | 2020-12-28 | $40K | — | Filing → |
| CLRB | BUY | 2020-06-08 | $150K | — | Filing → |
| CLRB | BUY | 2019-03-01 | $200 | — | Filing → |